Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Abstract EN

Background.

Urothelial carcinoma is the most common type of bladder cancer (BC).

It makes up more than 90% of all bladder cancers.

Uroplakins are tissue-specific, glycoproteins, playing a role in the construction and function of urothelium.

The emergence of uroplakins in the urine and/or plasma may be of potential importance in the early detection of BC.

In our study, the diagnostic value of plasma and urine uroplakin 2 (UP2) concentration in bladder cancer was investigated, with an assessment of the antioxidant potential of BC patients.

The correlation between UP2, total antioxidant capacity (TAC), and concentration of glutathione (GSH) was also examined.

Materials and Methods.

This study included 61 BC patients and 33 healthy controls.

UP2 concentration was estimated by the immunoenzymatic method (ELISA).

TAC and GSH were determined in spectrophotometrically methods.

Results.

UP2 concentration in BC patients was significantly higher (p≤0.001) both in plasma and in urine compared to the control groups (C).

TAC concentration in urine (p≤0.001) and GSH concentration in plasma (p=0.047) were significantly lower in BC group compared to the C group.

The high specificity and sensitivity for UPK2 in plasma (76%, 80%, respectively) and urine (88%, 84%, respectively) were observed.

Positive correlations were observed between concentration of UP2 in plasma and TAC concentration in urine and between UP2 concentration in plasma and GSH concentration in the same material.

Conclusion.

The study showed the early diagnostic value of urine and plasma UP2 in BC.

There was a decrease in UP2 concentration in the urine of patients with the development of BC.

The decrease of antioxidant systems (TAC, GSH) indicates their relationship with the BC process.

Based on the obtained results, it is justified to continue the study in a larger group of patients with BC.